

## **STEVEN P. TREON, MD, PHD, FRCP, FACP**

Dr. Steven P. Treon is the Director of the Bing Center for Waldenstrom's Macroglobulinemia (WM) at the Dana Farber Cancer Institute (DFCI), a Professor of Medicine at Harvard Medical School, and Chair of the WM Clinical Trials Group. Dr. Treon earned a B.A. (Biology), M.S. (Biochemistry), Ph.D. (Microbiology/Immunology), and M.D. with honors from Boston University, and a M.A. (Medical Sciences) degree from Harvard Medical School. He completed Internal Medicine residency at Boston University Medical Center, Hematology/Medical Oncology Fellowship at the Massachusetts General Hospital, and post-doctoral training at the Dana-Farber Cancer Institute. Dr. Treon oversees the WM clinic at the DFCI, which cares for over 1,000 WM patients worldwide. Most patients seen in the WM clinic enter Institutional Review Board approved studies on the genetic basis, pathogenesis and treatment of WM. Dr. Treon's laboratory first identified highly recurring activating mutations in MYD88 and CXCR4 using whole genome sequencing. His laboratory also identified that Bruton's tyrosine kinase (BTK) was a downstream target of mutated MYD88, and enabled a clinical trial with the BTK inhibitor ibrutinib that resulted in the first-ever approval of a drug by the U.S. FDA and the European Medicines Agency for WM. This study also showed that the mutation status of MYD88 and CXCR4 impacted treatment response in WM patients.

Dr. Treon also made major contributions to the investigation and advancement of many novel agents currently used in the treatment of WM. He was the principal investigator for prospective clinical trials that examined the monoclonal antibodies rituximab and alemtuzumab; the nucleoside analogue fludarabine with rituximab; the immunomodulatory agents thalidomide, lenalidomide, and pomalidomide with rituximab; the proteasome inhibitors bortezomib and carfilzomib alone and with rituximab; and the BTK inhibitor ibrutinib. He is currently evaluating the activity of the CXCR4 inhibitor ulocuplomb with ibrutinib in CXCR4 mutated WM patients, and the BCL-2 inhibitor venetoclax.

Dr. Treon has also been an active educator, and has taught broad audiences on the genetic basis, biology and therapy of WM. He has delivered numerous scientific and clinical lectures, and his scientific work in WM earned "Best of ASH" designations at the 2011 and 2013 Annual Meetings of the American Society of Hematology. He has also published extensively on topics in WM and related disorders, with over 250 peer-reviewed original reports, authoritative reviews, editorials, and chapters included in high-impact journals and textbooks. He has been the principal organizer of the International Workshops on WM, the main forum for the exchange of basic, translational and clinical trial advances in WM, as well as the organizer of the WM International Patient and Physicians Summits, which bring basic science and clinical advances directly from investigators to patients. His efforts in WM have been acknowledged by many awards including the Robert A. Kyle Award (2005), the Jan Gosta Waldenstrom Lifetime Achievement Award (2010), the Laurie Strauss Leukemia Foundation Outstanding Cancer Investigator Award (2011), designation as "America's Top Doctor" by U.S. News and World Report, the prestigious "One Hundred Award" from the

Massachusetts General Hospital for Outstanding Cancer Research (2012), the Bruce Waterfall Memorial Award from Weill Cornell Medical School (2016), the Medical Oncology Discoverer Award from the DFCI for seminal work in Medical Oncology (2016). In 2017, Dr. Treon was elected as a fellow to the Royal College of Physicians in London, and in 2018 as a fellow of the American College of Physicians. In 2019, Dr. Treon received the Distinguished Alumnus Award from Boston University Medical School in recognition of his work in Waldenstrom's Macroglobulinemia.